At a glance
ClinicalIndex Comparison RecordN/ACompleted· 19 enrolled
Drug / intervention
18FDG (an FDA-approved radiopharmaceutical)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Utility of FDG-PET and PET/CT in the Evaluation of Patients With Suspected Cholecystitis
In Brief
A clinical study evaluating 18FDG (an FDA-approved radiopharmaceutical) for Cholecystitis. Completed, enrolled 19 participants across 1 site.
Detailed Summary
This is a pilot study to investigate the ability of fluorodeoxyglucose-positron emission tomography (FDG-PET) and Positron emission tomography-computed tomography (PET/CT) as a direct method of detecting infection and/or inflammation of the gallbladder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCholecystitis
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2007
First PostedJan 2008
Primary CompletionJan 2010
Study CompletionJul 2010
TodayJul 2026
First PostedJan 10, 2008
Enrollment StartJul 1, 2007
Primary CompletionJan 1, 2010
Study CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 18.5 years ago
Interventions
18FDG (an FDA-approved radiopharmaceutical)drug
Route: Intravenous, Dosage: 5-10mCi, frequency: Single Administration